InvestorsHub Logo
Followers 176
Posts 16219
Boards Moderated 0
Alias Born 11/10/2008

Re: None

Wednesday, 01/25/2023 8:42:04 AM

Wednesday, January 25, 2023 8:42:04 AM

Post# of 21781
R&D is a VERY EXPENSIVE endeavor initially. It is not cost inhibitive. Owning shares is high risk at any stage until revenue is actually achieved from their product, period. Most often, a R&D Pinky is assured to depend on new shares to survive because there is typically little to no private funding sources other than through very dilutive agreements from the get-go.

Every retail trader doing so in Pinkyland MUST factor such risk in their personal performance expectations. High expectations beget high chance of losses.

The risk is most severe for retail investors presuming 'revenues soon' and a strong desire to enter on the bottom floor of a sky-rise ending. R&D endeavors are thankful for those $$ provided through extreme risk takers.

The assumption is that 'revenues' will occur is a must to remain as a SH. When is the kisser. GTCH has taken FOREVER to develop a revenue stream sufficient to remove their dependence on A/S. It remains the primary factor in providing sufficient funding for remaining a viable company.

When that dependency stops, that is when SHs begin to see a trace of share value appreciation. Will it happen? I sure hope so. Will it be sooner than later? I am banking on it.

Today's PR does not help matters. Strictly R&D with CYA written all over it. Good for the company while it only adds to the wait time to be borne by its SHs.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent GTCH News